Skip to content

Moderna’s PharmD Fellowship Program

Moderna, in collaboration with MCPHS University, offers a unique opportunity for PharmD graduates to gain rapid experience in the pharmaceutical industry with a focus on Regulatory Science while working on diverse projects to deepen their understanding of product development. Moderna will launch the fellowship program with 1 fellow starting in July 2022.

The Global Regulatory Science department at Moderna drives rapid and efficient development of molecules and medicinal products derived from an mRNA platform. We hope to ensure patient access to transformative therapies while building a sustainable and resilient function within Moderna. The fellow will join the Global Regulatory Science team, in Cambridge, Massachusetts.

During the 2-year fellowship, the fellow will focus on Regulatory Strategy and take part in projects covering 2-3 regulatory specialties, including:

  • Regulatory Advertising and Promotion
  • Regulatory Labeling
  • Regulatory Policy
  • Regulatory Operations
  • Regulatory CMC
  • International Regulatory Affairs

The fellow will be able to work directly with several experienced regulatory professionals in multiple specialties and across multiple therapeutic areas. Projects will be assigned based on the fellow’s areas of interest and available opportunities to build the fellow’s competencies as a regulatory professional. Additionally, the fellow will have the option to take part in a 1-3 month rotation in another department outside of Global Regulatory Science at Moderna.

Please see our brochure for additional details.

If you have any questions, please contact us at pharmd.fellowships@modernatx.com.

About Moderna

At Moderna, we believe messenger RNA (mRNA) is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

We are pioneering a new class of medicines made of mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed, and manufactured. Since our founding in 2010, we have worked to build an industry-leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development. Moderna’s mission is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Please visit our company website for more information.